Cancer Family
Malignant Musculoskeletal Neoplasm
CI-CAN-00000242Explore in graph →
141 active trials5 approved drugs46 evidence items
- NCIt
- C166357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000242Explore in graph →
Clinical trials
465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (58)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04475640 | Cancer Genetic Testing in Ethnic Populations | recruiting | N/A | 1,800 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03478462 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) |
| active not recruiting |
| Phase 1 |
| 30 |
| Cellectar Biosciences, Inc.INDUSTRY |
| 3 |
| Mar 18, 2026 |
| clinicaltrials |
| NCT05051059 | Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients(QOLSarcoma) | recruiting | N/A | 60 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05033288 | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone | recruiting | — | 72 | Mayo ClinicOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04307914 | Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases(FURTHER) | active not recruiting | N/A | 216 | UMC UtrechtOTHER | 4 | Mar 5, 2026 | clinicaltrials |
| NCT00186992 | Radiation Therapy to Treat Musculoskeletal Tumors | active not recruiting | Phase 2 | 202 | St. Jude Children's Research HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04055220 | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas(REGOSTA) | recruiting | N/A | 168 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04698785 | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients(REGOMAIN) | recruiting | Phase 2 | 36 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 42 | St. Jude Children's Research HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03296371 | Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma | active not recruiting | — | 900 | Children's Oncology GroupNETWORK | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04122872 | GISAR German Interdisciplinary Sarcoma Registry(GISAR) | recruiting | — | 9,000 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07355855 | A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma | not yet recruiting | Phase 2 | 106 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04845893 | Observational Study on Skeletal Ewing's Sarcoma(EWOss) | recruiting | — | 100 | Italian Sarcoma GroupNETWORK | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07264296 | Implant-Related Infections in Patients With Skeletal Sarcomas(IRISSAR) | enrolling by invitation | — | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02811523 | In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma | recruiting | Phase 1 | 17 | University Health Network, TorontoOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03160274 | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | recruiting | — | 2,000 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03244020 | LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology | enrolling by invitation | Phase 4 | 2,868 | Massachusetts General HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06528769 | Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma | recruiting | Phase 2 | 16 | Gabriel TinocoOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT02880319 | Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone | active not recruiting | Phase 2 | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07145931 | Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base | not yet recruiting | Phase 2 | 24 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07018960 | "Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)"(PRODIPET) | recruiting | N/A | 60 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07113301 | Incisional Biopsy Versus Core-needle Biopsy in Bone Tumors Analysis(INSPECTOR) | active not recruiting | — | 42 | Istituto Ortopedico RizzoliOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05947149 | HRQoL in Patients With Solid Tumors Treated With Hadrontherapy(HadroQoL) | recruiting | — | 180 | CNAO National Center of Oncological HadrontherapyOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06522165 | Pediatric Oncological Orthopaedic Reconstruction | active not recruiting | — | 400 | Costantino ErraniOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06875700 | Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients | recruiting | — | 300 | University of UtahOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05427461 | Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2(SAMHY2) | active not recruiting | N/A | 20 | Institut Claudius RegaudOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01793168 | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford(CoRDS) | recruiting | — | 20,000 | Sanford HealthOTHER | 2 | May 29, 2025 | clinicaltrials |
| NCT06932861 | Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma | not yet recruiting | Early Phase 1 | 5 | Xinxin ZhangOTHER | 0 | Apr 22, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 2, 2026source: clinicaltrials